{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:06Z","timestamp":1790739426227,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["EJP RD COFUND-EJP N\u00b0 825575"],"award-info":[{"award-number":["EJP RD COFUND-EJP N\u00b0 825575"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Academic-sponsored trials for rare diseases face many challenges; the present paper identifies hurdles in the set-up of six multinational clinical trials for drug repurposing, as use cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Six academic-sponsored multinational trials aiming to generate knowledge on rare diseases drug repurposing were used as examples to identify problems in their set-up. Coordinating investigators leading these trials provided feedback on hurdles linked to study, country, and site set up, on the basis of pre-identified categories established through the analysis of previous peer-reviewed publications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Administrative burden and lack of harmonization for trial-site agreements were deemed as a major hurdle. Other main identified obstacles included the following: (1) complexity and restriction on the use of public funding, especially in a multinational set up, (2) drug supply, including procurement tendering rules and country-specific requirements for drug stability, and (3) lack of harmonization on regulatory requirements to get trial approvals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A better knowledge of the non-commercial clinical research landscape and its challenges and requirements is needed to make drugs\u2014especially those with less commercial gain\u2014accessible to rare diseases patients. Better information about existing resources like research infrastructures, clinical research programs, and counseling mechanisms is needed to support and guide clinicians through the many challenges associated to the set-up of academic-sponsored multinational trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06713-y","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:02:27Z","timestamp":1663268547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-9990","authenticated-orcid":false,"given":"Marta","family":"del \u00c1lamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"B\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Griese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sangiorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Halftermeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Souckov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Noskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Demlov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"1","key":"6713_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1740774507087704","volume":"5","author":"L Duley","year":"2008","unstructured":"Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008;5(1):40\u20138.","journal-title":"Clin Trials"},{"issue":"1","key":"6713_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13063-017-2099-9","volume":"18","author":"S Djurisic","year":"2017","unstructured":"Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, et al. Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 2017;18(1):360.","journal-title":"Trials."},{"issue":"1","key":"6713_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s13063-017-2287-7","volume":"18","author":"A Rath","year":"2017","unstructured":"Rath A, Salamon V, Peixoto S, Hivert V, Laville M, Segrestin B, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18(1):556.","journal-title":"Trials."},{"issue":"1","key":"6713_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","volume":"17","author":"C Alemayehu","year":"2018","unstructured":"Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries- a systematic review. Int J Equity Health. 2018;17(1):37.","journal-title":"Int J Equity Health"},{"issue":"12","key":"6713_CR5","doi-asserted-by":"publisher","first-page":"e0145122","DOI":"10.1371\/journal.pone.0145122","volume":"10","author":"I Atal","year":"2015","unstructured":"Atal I, Trinquart L, Porcher R, Ravaud P. Differential globalization of industry- and non-industry\u2013sponsored clinical trials. Lexchin J, editor. PLoS One. 2015;10(12):e0145122.","journal-title":"PLoS One"},{"key":"6713_CR6","doi-asserted-by":"publisher","first-page":"746987","DOI":"10.3389\/fphar.2021.746987","volume":"12","author":"S van den Berg","year":"2021","unstructured":"van den Berg S, de Visser S, Leufkens HGM, Hollak CEM. Drug repurposing for rare diseases: a role for academia. Front Pharmacol. 2021;12:746987.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6713_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13063-020-4188-4","volume":"21","author":"M Griese","year":"2020","unstructured":"Griese M, K\u00f6hler M, Witt S, Sebah D, Kappler M, Wetzke M, et al. Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. Trials. 2020;21(1):307.","journal-title":"Trials."},{"issue":"1","key":"6713_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13023-022-02399-2","volume":"17","author":"M Griese","year":"2022","unstructured":"Griese M, Kappler M, Stehling F, Schulze J, Baden W, Koerner-Rettberg C, et al. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. Orphanet J Rare Dis. 2022;17(1):289.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"6713_CR9","doi-asserted-by":"publisher","first-page":"e021749","DOI":"10.1136\/bmjopen-2018-021749","volume":"8","author":"C B\u00fchrer","year":"2018","unstructured":"B\u00fchrer C, Erdeve \u00d6, Bassler D, Bar-Oz B. Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial. BMJ Open. 2018;8(7):e021749.","journal-title":"BMJ Open"},{"key":"6713_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fneur.2019.00293","volume":"10","author":"P Lingor","year":"2019","unstructured":"Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, et al. ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Front Neurol. 2019;10:293.","journal-title":"Front Neurol"},{"issue":"1","key":"6713_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","volume":"20","author":"S Nagy","year":"2019","unstructured":"Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Sch\u00e4delin S, Bieri O, et al. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 2019;20(1):637.","journal-title":"Trials."},{"issue":"2","key":"6713_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/annrheumdis-2014-206033","volume":"75","author":"LR Ranganath","year":"2016","unstructured":"Ranganath LR, Milan AM, Hughes AT, Dutton JJ, Fitzgerald R, Briggs MC, et al. Suitability of Nitisinone in Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4\u00a0weeks of treatment. Ann Rheum Dis. 2016;75(2):362.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6713_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S2213-8587(20)30228-X","volume":"8","author":"LR Ranganath","year":"2020","unstructured":"Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Br\u00f6ijers\u00e9n A, et al. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diab Endocrinol. 2020;8(9):762\u201372.","journal-title":"Lancet Diab Endocrinol"},{"issue":"2\u20133","key":"6713_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmjinnov-2018-000324","volume":"5","author":"T Cox","year":"2019","unstructured":"Cox T, Psarelli EE, Taylor S, Shepherd HR, Robinson M, Barton G, et al. Subclinical ochronosis features in alkaptonuria: a cross-sectional study. BMJ Innov. 2019;5(2\u20133):82.","journal-title":"BMJ Innov"},{"issue":"1","key":"6713_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13063-018-2645-0","volume":"19","author":"RA Crow","year":"2018","unstructured":"Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions\u2014lessons learned from the FOR-DMD trial. Trials. 2018;19(1):291.","journal-title":"Trials."},{"issue":"5\u20136","key":"6713_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/21678421.2021.1879866","volume":"22","author":"P Lingor","year":"2021","unstructured":"Lingor P, Koch JC, Statland JM, Hussain S, Hennecke C, Wuu J, et al. Challenges and opportunities for multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotrop Lateral Sclerosis Frontotemp Degen. 2021;22(5\u20136):419\u201325.","journal-title":"Amyotrop Lateral Sclerosis Frontotemp Degen"},{"issue":"1","key":"6713_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","volume":"96","author":"RC Griggs","year":"2009","unstructured":"Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20\u20136.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"6713_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-018-0820-8","volume":"13","author":"RD Hilgers","year":"2018","unstructured":"Hilgers RD, Bogdan M, Burman CF, Dette H, Karlsson M, K\u00f6nig F, et al. Lessons learned from IDeAl \u2014 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. Orphanet J Rare Dis. 2018;13(1):77.","journal-title":"Orphanet J Rare Dis"},{"issue":"nov24 15","key":"6713_CR19","doi-asserted-by":"publisher","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349(nov24 15):g6802.","journal-title":"BMJ"},{"issue":"1","key":"6713_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-018-0919-y","volume":"13","author":"T Friede","year":"2018","unstructured":"Friede T, Posch M, Zohar S, Alberti C, Benda N, Comets E, et al. Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet J Rare Dis. 2018;13(1):186.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"6713_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","volume":"13","author":"S Day","year":"2018","unstructured":"Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I, Larsson K, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13(1):195.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"6713_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrd4319","volume":"13","author":"P Bauer","year":"2014","unstructured":"Bauer P, K\u00f6nig F. The risks of methodology aversion in drug regulation. Nat Rev Drug Discov. 2014;13(5):317\u20138.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"6713_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drudis.2020.10.017","volume":"26","author":"V Starokozhko","year":"2021","unstructured":"Starokozhko V, Kallio M, Howell \u00c5K, Salmi AM, Andrew-Nielsen G, Goldammer M, et al. Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap. Drug Discov Today. 2021;26(2):283\u20138.","journal-title":"Drug Discov Today"},{"key":"6713_CR24","doi-asserted-by":"publisher","first-page":"817663","DOI":"10.3389\/fmed.2021.817663","volume":"8","author":"C Asker-Hagelberg","year":"2022","unstructured":"Asker-Hagelberg C, Boran T, Bouygues C, Eskola SM, Helmle L, Hern\u00e1ndez C, et al. Repurposing of medicines in the EU: launch of a pilot framework. Front Med. 2022;8:817663.","journal-title":"Front Med"},{"issue":"1","key":"6713_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12914-015-0073-8","volume":"15","author":"R Ravinetto","year":"2015","unstructured":"Ravinetto R, De Nys K, Boelaert M, Diro E, Meintjes G, Adoke Y, et al. Sponsorship in non-commercial clinical trials: definitions, challenges and the role of good clinical practices guidelines. BMC Int Health Hum Rights. 2015;15(1):34.","journal-title":"BMC Int Health Hum Rights"},{"key":"6713_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2020.11.007","volume":"131","author":"B Speich","year":"2021","unstructured":"Speich B, Logullo P, Deuster S, Marian IR, Moschandreas J, Taji Heravi A, et al. A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials. J Clin Epidemiol. 2021;131:70\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"9810","key":"6713_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0140-6736(12)60024-5","volume":"379","author":"M Christensen","year":"2012","unstructured":"Christensen M, Knop FK. The unobtainable placebo: control of independent clinical research by industry? Lancet. 2012;379(9810):30.","journal-title":"Lancet"},{"key":"6713_CR28","unstructured":"Classification and analysis of the GCP inspection findings of GCP inspections conducted at the request of the CHMP. 2014 INS\/GCP\/46309\/2012 Compliance and Inspections."},{"key":"6713_CR29","unstructured":"The European Parlament and the European Union. Regulation (EU) No 536\/2014 of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. 2014;"},{"issue":"5","key":"6713_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd3202-c2","volume":"11","author":"H Krafft","year":"2012","unstructured":"Krafft H, B\u00e9lorgey C, Szalay G. Experience and further development with the voluntary harmonization procedure for multinational clinical trials in the European Union. Nat Rev Drug Discov. 2012;11(5):419.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"6713_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrd3202-c1","volume":"10","author":"G Amexis","year":"2011","unstructured":"Amexis G, Schmitt E. A sponsor\u2019s experience with the voluntary harmonization procedure for clinical trial applications in the European Union. Nat Rev Drug Discov. 2011;10(5):393.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"6713_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmi.2021.10.011","volume":"28","author":"A Diallo","year":"2022","unstructured":"Diallo A, Tr\u00f8seid M, Simensen VC, Boston A, Demotes J, Olsen IC, et al. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect. 2022;28(1):1\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"6713_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1740774510376547","volume":"7","author":"JD Neaton","year":"2010","unstructured":"Neaton JD, Babiker A, Bohnhorst M, Darbyshire J, Denning E, Frishman A, et al. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials. 2010;7(6):705\u201318.","journal-title":"Clin Trials"},{"issue":"1","key":"6713_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s13063-019-3702-z","volume":"20","author":"A Magnin","year":"2019","unstructured":"Magnin A, Iversen VC, Calvo G, \u010ce\u010detkov\u00e1 B, Dale O, Demlova R, et al. European survey on national training activities in clinical research. Trials. 2019;20(1):616.","journal-title":"Trials."},{"key":"6713_CR35","unstructured":"Minimum Criteria for ICH E6 (R2) GCP Investigator Site Personnel Training (Excerpt from TransCelerate BioPharma Operating Principles). Version 2.0 [Internet]. 2017. Available from: https:\/\/www.transceleratebiopharmainc.com\/wp-content\/uploads\/2017\/03\/GCP-MR-Minimum-Criteria-R2_FINAL.pdf"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06713-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:06:31Z","timestamp":1663268791000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6713"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06713-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"783"}}